Identification of Clinical Prognostic Factors in Patients with Unknown Primary Tumors Treated with a Platinum-Based Combination

Publisher： Karger

E-ISSN： 1423-0232|69|2|135-144

ISSN： 0030-2414

Source： Oncology, Vol.69, Iss.2, 2005-09, pp. : 135-144

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (ELECTRONIC), Vol. 44, Iss. S1, 2017-12 ,pp. : 21-29

John Wiley & Sons Inc

Access to resources Recommend Favorite

Borderline Tumors of the Ovary: Clinical Course and Prognostic Factors

Oncology Research and Treatment, Vol. 35, Iss. 1-2, 2012-01 ,pp. : 28-33

Karger

Access to resources Recommend Favorite

Angiogenesis in unknown primary tumors

By Longo Vito

Clinical and Experimental Medicine, Vol. 12, Iss. 2, 2012-06 ,pp. : 67-68

Springer Publishing Company

Access to resources Recommend Favorite

An ERCC4 regulatory variant predicts grade‐3 or ‐4 toxicities in patients with advanced non‐small cell lung cancer treated by platinum‐based therapy

INTERNATIONAL JOURNAL OF CANCER, Vol. 142, Iss. 6, 2018-03 ,pp. : 1218-1229

John Wiley & Sons Inc

Access to resources Recommend Favorite

Age and drug therapy are key prognostic factors for first clinical fracture in patients with primary osteoporosis

By Gajic-Veljanoski O. Sebaldt R. Davis A. Tritchler D. Tomlinson G. Petrie A. Adachi J. Cheung A.

Osteoporosis International, Vol. 18, Iss. 8, 2007-08 ,pp. : 1091-1100

Springer Publishing Company

Access to resources Recommend Favorite